FINHUB Insights

BMY · Q2 FY26 · Apr 1 – Jun 30, 2026

Bristol Myers Squibb Q2 FY26: where the revenue came from and where it went

Bristol Myers Squibb Q2 FY26: revenue $13B (+6% year over year). Net profit $3.3B. Largest cohort Growth Portfolio $7.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Jul 30, 2026 10-Q
Sankey diagram of Bristol Myers Squibb's income statement for Q2 FY26: revenue of $13 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$13B +6% year over year
Gross profit$9.2B 71% margin
Operating profit$-0.8B -6% margin
Net profit$3.3B 26% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 13 100% +6%
Growth Portfolio 7.6 58%
Eliquis 4.5 35%
Revlimid 0.4 3% −49%
Pomalyst/Imnovid 0.2 2% −71%
Other Legacy products 0.2 2% −24%
Sprycel 0.1 1% −27%
Abraxane 0.1 1% −48%
Cost of revenue−3.728%
Gross profit9.271% margin−1pp
Research & development−323%+2pp
SG&A−1.814%+0pp
Other−5.341%+0pp
Operating profit-0.8-6% margin+0pp
Tax−0.8
Net profit3.326%+15pp
Filing on EDGAR More quarters of BMY

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters